Table 3.
Response rate and survival according to prognostic factors
|
Characteristic |
Response CR/CRu/PR |
1-year progression free survival |
2-year overall survival |
||||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | P | N | % | P | N | % | P | |
| Time to relapse after diagnosis, months |
|
|
|
|
|
|
|
|
|
| <12 |
33 |
35 |
<0.001 |
15 |
16 |
<0.001 |
7 |
7 |
<0.001 |
| ≥12 |
47 |
68 |
|
46 |
67 |
|
35 |
51 |
|
| Prior rituximab treatment |
|
|
|
|
|
|
|
|
|
| No |
63 |
67 |
<0.001 |
38 |
40 |
0.355 |
20 |
21 |
0.126 |
| Yes |
17 |
25 |
|
23 |
33 |
|
22 |
32 |
|
| SaaIPI at relapse |
|
|
|
|
|
|
|
|
|
| 2–3 |
16 |
27 |
<0.001 |
10 |
17 |
<0.001 |
5 |
9 |
<0.001 |
| 0–1 |
64 |
67 |
|
51 |
49 |
|
37 |
36 |
|
| ALC/AMC ratio |
|
|
|
|
|
|
|
|
|
| <2.0 |
20 |
27 |
<0.001 |
9 |
12 |
<0.001 |
3 |
4 |
<0.001 |
| ≥2.0 |
60 |
67 |
|
52 |
58 |
|
39 |
43 |
|
| Absolute monocyte count |
|
|
|
|
|
|
|
|
|
| ≥530/ul |
21 |
33 |
<0.001 |
13 |
20 |
<0.001 |
6 |
9 |
<0.001 |
| <530/ul |
59 |
60 |
|
48 |
49 |
|
36 |
36 |
|
| Absolute lymphocyte count |
|
|
|
|
|
|
|
|
|
| <1120/ul |
41 |
41 |
0.015 |
27 |
27 |
0.001 |
15 |
15 |
<0.001 |
| ≥1120/ul |
39 |
61 |
|
34 |
53 |
|
27 |
42 |
|
| LDH at relapse |
|
|
|
|
|
|
|
|
|
| >Normal |
16 |
28 |
<0.001 |
12 |
21 |
0.001 |
9 |
16 |
0.026 |
| ≤Normal |
64 |
61 |
|
49 |
47 |
|
33 |
31 |
|
| Rituximab containing salvage therapy |
|
|
|
|
|
|
|
|
|
| No |
55 |
46 |
0.166 |
39 |
33 |
0.036 |
22 |
18 |
<0.001 |
| Yes | 25 | 58 | 22 | 51 | 20 | 47 | |||
Abbreviations:CR complete remission, CRu unconfirmed complete remission, PR partial response, saaIPI second-line age-adjusted International Prognostic Index, ALC/AMC ratio absolute lymphocyte count/absolute monocyte count ratio, LDH lactate dehydrogenase.